Vizsgálati helyszín
University Hospital Of Canary Islands
San Cristobal De La Laguna, 38320, SpanyolországMég nincs intézményhez kötve
- 18futó vizsgálat
- 7lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis3 vizsgálat
- 4. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Toboroz8 vizsgálat
- Lezárult7 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche3 vizsgálat
- Kymera Therapeutics Inc.2 vizsgálat
- SOLTI Breast Cancer Research Group2 vizsgálat
- Amgen1 vizsgálat
- BioNTech SE1 vizsgálat
- és még 16
Futó vizsgálatok
Még nem toboroz
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00· 2. fázis· Kymera Therapeutics Inc.· Forrás
Toboroz
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
2025-523180-38-00· 2. fázis· Kymera Therapeutics Inc.· Forrás
Toboroz
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHYPERTHERMIA (QH) WITH MITOMYCIN-C PRIOR TO TRANSURETHRAL BLADDER RESECTION IN A MAJOR OUTPATIENT SURGERY PROGRAMME AND TREATMENT WITH MITOMYCIN-C IN NORMOTHERMIA POST-RESECTION.
2024-519890-21-00· 4. fázis· University Hospital Of Canary Islands· Forrás
Fut, nem toboroz
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· 2/3. fázis· St. Anna Childrens Cancer Research Institute GmbH· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· 3. fázis· ViiV Healthcare· Forrás
Toboroz
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
NCT05874401· 4. fázis· Pharmacosmos A/S· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2
2022-500861-29-00· 3. fázis· Celgene Corp.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Meghívásos bevonás
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· 3. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT04759248· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Fut, nem toboroz
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT04053322· 2. fázis· UNICANCER· Forrás
Toboroz
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· 2/3. fázis· Centre Leon Berard· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek